Codexis completes obligations under R&D agreement with leading biopharmaceutical company
Enzyme developed with CodeEvolver technology for preclinical therapeutics program exceeds agreement requirements.
FDA clears SPR Therapeutics pain management device
Minimally invasive, non-opioid alternative, stimulates peripheral nerves to provide sustained relief of chronic and acute pain.
New studies suggest relationship between tau pathology and progression of Alzheimer's disease
Analysis shows a correlation between tau tangles and cognitive decline in patients living with Alzheimer's disease.
Sanofi receives FDA approval of Adlyxin for treatment of adults with type 2 diabetes
Adlyxin is approved as Lyxumia in more than 60 countries.
Slovakia-based CDMO sells registration dossiers for more than 20 pharma products
The portfolio of products will be marketed by Xantis Pharma throughout Central and Eastern Europe.
John C. Lechleiter to retire as Lilly CEO; Board elects David A. Ricks as successor
Ricks will assume President and CEO roles on 1 January 2017, and become chairman of Lilly's board on 1 June 2017.
GSK announces significant new investment in UK manufacturing network
Investment in advanced manufacturing of new respiratory and biopharmaceuticals portfolio.
NeuroDerm issued a new US patent for aqueous apomorphine covering concentrated subcutaneously delivered pharmaceutical compositions
Company's ND0701 formulation intended for chronic therapy of Parkinson's disease and is developed for continuous subcutaneous administration by a small, low-volume, disposable patch-pump.
Cytokinetics and Astellas announce option right for tirasemtiv and expansion of global collaboration for CK-2127107 in ALS
Cytokinetics to receive $65 million in upfront payments and $30 million in additional sponsored R&D; potential for more than $100 million in payments associated with the exercise of the option.